Last week, the “International Summit on Human Gene Editing” was jointly convened by the Chinese Academy of Sciences, UK’s Royal Society, the U.S. National Academy of Sciences and the U.S. National Academy of Medicine. Sam Nunn School of International Affairs Associate Professor Margaret Kosal was one of 500 invited participants from more than 20 nations there to take part in discussions on the future of human gene editing and “designer babies.”
New technologies often bring new ways of doing things and improvements to health through new therapeutics. They also sometimes create new fears about unintended consequences, new weapons and broad ethical concerns. That’s why I participated in a global discussion on the scientific, ethical and governance issues associated with human gene-editing research and biomedical clinical uses of some of the newest biotechnologies.